Fluidigm Announces Pricing of Public Offering of 8,150,000 Shares of Common Stock

PDF Version SOUTH SAN FRANCISCO, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the pricing of an underwritten public offering of 8,150,000 shares of its common stock at a price to the public of $6.75 per share for aggregate gross proceeds of approximately $55 million. Fluidigm has granted to the underwriters... Read more

Fluidigm Announces Commencement of Public Offering of Common Stock

PDF Version SOUTH SAN FRANCISCO, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering pursuant to Fluidigm’s existing shelf registration statement. In connection with... Read more

The Native Antigen Company launches new Zika immunoassays with unprecedented specificity and sensitivity

29 November 2018, Oxford, UK – The Native Antigen Company has launched a series of ground-breaking immunoassays for Zika virus, offering researchers in academia, public health and drug discovery the capability to work with unprecedented levels of specificity and sensitivity. Unlike previous methods, the new assays have little or no cross-reactivity with other flaviviruses, including... Read more

Axol Bioscience Launches Human iPSC-derived Microglia

Cambridge, UK – (6th December 2018) – Axol Bioscience, the human cell culture specialist, is launching a new line of Human induced Pluripotent Stem Cells (iPSC)-derived Microglia for the consistent and reproducible study of neuroglia and their involvement in neurodegenerative diseases, including Alzheimer’s disease, multiple sclerosis and Parkinson’s disease. Microglia are commonly described as the... Read more

Agilent Expands Cell Analysis R&D Capabilities in Ireland

Agilent Expands Cell Analysis R&D Capabilities in Ireland New facility incorporates recently acquired Luxcel Biosciences SANTA CLARA, Calif., November 16, 2018 Agilent Technologies Inc. (NYSE: A) today announced the opening of a new, purpose-built extension to its Little Island, Cork facility in Ireland. The campus will focus on developing advanced technologies for the analysis of... Read more

Abcam appoints Cheri Walker, PhD, as Senior Vice President, Corporate Development

Cambridge, UK – 30 October 2018: Abcam plc, a global innovator in life science reagents and tools, announced today that it has appointed Cheri Walker, PhD, to the role of Senior Vice President, Corporate Development.   Cheri is an accomplished industry professional with over 20 years’ experience in the life sciences tools and diagnostics sector. She... Read more

Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System

PDF Version Providing the largest source of standardized, multi-omic immune data from healthy human subjects to accelerate translational research SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technology, today announced the publication of the 10,000 Immunomes Project (10KIP), a seminal human immune reference standard containing mass cytometry immune cell profiles,... Read more

ZEISS laser manipulation system based on Nobel Prize-winning “optical tweezer” technology

Using light to capture and manipulate tiny objects Knowledge News The 2018 Nobel Prize in Physics was awarded to Arthur Ashkin of the United States, Gérard Mourou of France, and Donna Strickland of Canada for groundbreaking inventions in the field of laser physics. The Nobel committee recognized Dr. Ashkin for his work on turning laser light into... Read more

Lonza to Reveal Next-Generation Electronic Batch Record Execution Platform at Cell and Gene Therapy Manufacturing Forum 2018

October 19,2018 Product News PDF Walkersville, MD (USA) / Basel (CH), 19 October 2018– Lonza will unveil its next-generation electronic batch record execution platform, the MODA-ES™ Software Platform, at the Cell & Gene Therapy Manufacturing Forum from 13-15 November 2018, in London (UK). Building on Lonza’s extensive informatics know-how and vast experience as a contract manufacturing... Read more

MilliporeSigma Announces Agreement to Sell Amnis® Flow Cytometry and Guava® Technologies Businesses to Luminex Corporation

All associated reagents under these brands included in the deal Strategic agreement allows Luminex to increase footprint in multi-billion-dollar flow cytometry market Deal expected to close at end of 2018 Burlington, Massachusetts, October 18, 2018 — MilliporeSigma today announced the signing of a definitive agreement to sell its Flow Cytometry unit to Luminex Corporation for $75... Read more